← Back to the report

Medtronic plc

Healthcare · Generated 16 November 2026

Medtronic plc (NYSE: MDT): Deep Dive Research Report

Healthcare / Medical Devices. Report date: 16 November 2026.

Which reporting period is the latest. Medtronic's fiscal year ends on the last Friday of April, and it reports quarterly. FY2027 has 53 weeks. Its first quarter ended 31 July 2026 and was reported on 1 September 2026. The second quarter ends 30 October 2026, and the company has scheduled the Q2 FY27 release for 24 November 2026. That date is after today, so the Q1 FY27 release and call is the newest results event. The six periods used in this report are:

  • Q4 FY25: 21 May 2025
  • Q1 FY26: 19 August 2025
  • Q2 FY26: 18 November 2025
  • Q3 FY26: 17 February 2026
  • Q4 FY26: 3 June 2026
  • Q1 FY27: 1 September 2026

1. What the Company Does

Medtronic makes things that doctors put inside people, or use on people during surgery, so that a failing body part works again. Examples include:

  • a pacemaker the size of a vitamin capsule that keeps a slow heart beating;
  • a catheter that kills the misfiring heart tissue causing atrial fibrillation;
  • a wire-thin electrode that calms the tremor of Parkinson's disease;
  • a stapler and an energy device that seal blood vessels during a bowel resection;
  • a navigation camera and robot arm that guide a spine surgeon's screw to within a millimetre of where it should go.

It sells these to hospitals and surgery centres in more than 150 countries, and it is paid mostly per procedure. Every implant, catheter or cartridge is consumed by one patient, so revenue tracks how many procedures are done and which tools surgeons choose to do them with.

Origins. The company began on 29 April 1949, when Earl Bakken and his brother-in-law Palmer Hermundslie formed a partnership in a Minneapolis garage to repair hospital electronics (Wikipedia, Earl Bakken; Medtronic, Celebrating Earl Bakken). The turning point came in 1957. A power blackout in the Twin Cities killed a child whose heart was being paced by a wall-powered machine, and the cardiac surgeon C. Walton Lillehei asked Bakken for something better. Within weeks Bakken produced the first wearable, battery-powered, transistorised pacemaker (IEEE Spectrum). Medtronic commercialised an implantable pacemaker around 1960. For decades the company's identity was electrical stimulation of the body: pacing the heart first, then the spinal cord, the brain and the bladder. That lineage still explains most of the company's engineering culture today.

Milestones that shaped today's company

  • Covidien (2015). The acquisition added a huge surgical-instruments and patient-monitoring business. Medtronic went from a cardiac and neuro device maker to a company that also sells staplers, energy devices, hernia mesh, pulse oximeters and airway products. The deal also moved the parent's legal home to Ireland, which is why the company is "Medtronic plc" with its registered office in Galway (Wikipedia, Medtronic).
  • A decade of portfolio pruning. Medtronic has been selling or exiting slower businesses. The latest and largest step is the diabetes business: Medtronic announced the separation in May 2025, listed it on Nasdaq as MiniMed Group (MMED) in March 2026, and fully exited it in October 2026 through an exchange offer. That sequence is explained in Section 2.

The problem it solves. Medtronic's core proposition is a durable therapy for a chronic condition that drugs either cannot fix or fix poorly:

  • heart rhythm disorders;
  • drug-resistant hypertension;
  • chronic pain;
  • movement disorders;
  • incontinence;
  • degenerative spine disease.

Its other proposition, inherited from Covidien, is the everyday plumbing of surgery: the stapler, sealer and monitor a hospital uses thousands of times a year. The customer is a physician who wants a reliable tool with clinical evidence behind it, and a hospital that wants that tool reimbursed, in stock and supported.

Why it is hard to replicate. A device that sits inside a beating heart for a decade has to be proven in randomised trials, approved by the FDA and its foreign equivalents, made under audited quality systems, and supported in the operating room by a trained representative. Each new therapy takes years of trials and regulatory work before the first sale, and a quality failure can cost a franchise (Section 8). Section 3 covers the operational detail.

A concrete example. Take a 68-year-old with paroxysmal atrial fibrillation whose drugs have stopped working. She is referred to an electrophysiologist, who books a catheter ablation:

  1. In the lab, the physician threads a Medtronic Sphere-9 catheter up the femoral vein and across into the left atrium.
  2. The Affera mapping system builds a 3D electrical map of her heart on screen.
  3. The same catheter that mapped the tissue delivers pulsed electric fields that kill the misfiring cells around the pulmonary veins, without the heat that can damage the oesophagus.
  4. The procedure is shorter than the older thermal approach.
  5. She may also leave with a LINQ insertable monitor under the skin, so Medtronic's remote-monitoring network can tell her doctor if the arrhythmia returns.

The disposables in that one case come from Medtronic: catheter, sheath and monitor. So does the capital equipment the hospital has installed, the mapping console and generator. The next case in that lab will most likely use the same platform.


2. Business Segments

From FY2027 Medtronic reports three portfolios: Cardiovascular, Neuroscience and Medical Surgical. Diabetes was a fourth segment through FY2026 and stayed consolidated until the October 2026 split-off. All shares below are of FY2026 net sales from the Q4 FY26 earnings release.

PortfolioShare of FY26 salesPro forma ex-DiabetesRole in the group
Cardiovascular~38%~42%Growth engine (ablation, pacing, renal denervation)
Neuroscience~28%~31%Mixed: fast-growing spine/robotics, soft neuromodulation
Medical Surgical~24%~27%Cash generator with a robotics option (Hugo)
Diabetes (MiniMed)~9%gone since Oct 2026Separated

Cardiovascular (~38% of FY26 sales)

What it does. Through FY26 there were three operating units:

  • Cardiac Rhythm & Heart Failure (~21% of group sales): pacemakers, including the leadless Micra; implantable defibrillators, including the extravascular Aurora; insertable cardiac monitors (LINQ); remote monitoring; and the cardiac ablation business (pulsed field ablation through Affera and PulseSelect).
  • Structural Heart & Aortic (~10%): the Evolut transcatheter aortic valve (TAVR), surgical valves and aortic stent grafts.
  • Coronary & Peripheral Vascular (~7%): coronary stents and balloons, peripheral devices, and the Symplicity Spyral renal denervation system, which Medtronic markets under the Ardian name.

In FY27 the company re-cut the portfolio into four reporting units: Electrophysiology Therapies, Interventional Cardiology Therapies, CardioVascular Surgery and Peripheral Vascular Health (Q1 FY27 release). The new structure groups ablation with pacing under one electrophysiology heading and puts the hypertension and structural franchises together in interventional cardiology.

Customers and end markets. Hospital electrophysiology labs, cath labs and cardiac surgery suites. The physicians who choose the devices are electrophysiologists, interventional cardiologists and cardiac surgeons.

Core capability. Seventy years of building long-lived electrical implants, plus a remote-monitoring network that ties those implants to clinics. Few rivals have both an implant line and an ablation line feeding the same electrophysiologist. That pairing is what makes the pulsed-field-ablation (PFA) push credible.

Why it is separate, and its role. Cardiovascular has its own call points, its own reimbursement codes and its own clinical-trial machinery. Management treats it as the group's growth engine. In Q1 FY27 it grew fastest of the three portfolios, led by ablation.

Main rivals: Boston Scientific, Abbott, Johnson & Johnson MedTech, Edwards Lifesciences (valves), Recor (renal denervation).

Neuroscience (~28% of FY26 sales)

What it does

  • Cranial & Spinal Technologies (~14% of group sales): spinal implants, plus the enabling technology around them. That includes the StealthStation navigation system, the O-arm imaging system, the Mazor spine robot and, since FY26, the Stealth AXiS platform.
  • Specialty Therapies (~8%): neurovascular devices for stroke and aneurysm, ear-nose-throat products, and pelvic health. Pelvic health includes the InterStim sacral nerve stimulator and the new Altaviva tibial implant for urge incontinence.
  • Neuromodulation (~6%): spinal cord stimulators for chronic pain, including the closed-loop Inceptiv, and deep brain stimulation, including BrainSense adaptive DBS.

Customers and end markets. Neurosurgeons, orthopaedic spine surgeons, interventional neuroradiologists, urologists, urogynaecologists and pain physicians, working in hospitals and ambulatory surgery centres.

Core capability. Medtronic is unusual in selling the spine implant together with the imaging, navigation and robot used to place it. A hospital that owns the capital system tends to buy the screws that work with it.

Why it is separate, and its role. Neuroscience combines a fast-growing enabling-technology business (spine robotics) with a soft one (neuromodulation). Management talks about it as a robotics and ecosystem story more than an implant story.

Main rivals: Globus Medical, Stryker, Johnson & Johnson MedTech (DePuy Synthes), Boston Scientific and Abbott (neuromodulation), Axonics (now part of Boston Scientific) in pelvic health.

Medical Surgical (~24% of FY26 sales)

What it does

  • Surgical & Endoscopy (~19% of group sales): the former Covidien surgical line. That means staplers, LigaSure vessel sealing, Valleylab energy, hernia mesh and GI endoscopy products. It also includes the Hugo robotic-assisted surgery system and the Touch Surgery video and analytics platform.
  • Acute Care & Monitoring (~6%): Nellcor pulse oximetry, capnography, airway products and related monitoring.

Customers and end markets. Hospital operating rooms and ICUs, mostly through group purchasing contracts.

Core capability. Very large-scale manufacturing of high-volume disposables, and the installed relationships that come with being in almost every operating room. Hugo is the attempt to turn that disposable franchise into a robotic platform.

Why it is separate, and its role. It came from a different company (Covidien), it is bought by a different buyer (the hospital's supply chain more than an individual implanting physician), and it has different economics (volume and contract pricing). Its job in the group is to throw off cash. Hugo is the strategic option inside it.

Main rivals: Johnson & Johnson MedTech (Ethicon), Intuitive Surgical (robotics), Stryker, Olympus, Masimo (oximetry).

Diabetes (MiniMed), ~9% of FY26 sales, now separated

MiniMed made insulin pumps, continuous glucose monitors and the software linking them. The sequence of the exit:

  1. May 2025: Medtronic announced it would separate the business within 18 months.
  2. March 2026: MiniMed Group listed on Nasdaq at US$20 per share. The IPO sold about 10% and Medtronic kept roughly 90% (Investing.com).
  3. October 2026: Medtronic exchanged its entire remaining stake for its own shares in a split-off. The final exchange ratio was 4.5939 MiniMed shares per Medtronic share (Medtronic, 7 Oct 2026). The offer was 5.4 times subscribed. Medtronic accepted 55,032,401 of its own ordinary shares and handed over 252,813,348 MiniMed shares.
  4. 15 October 2026: the separation completed, and "Medtronic no longer holds an equity stake in MiniMed" (MiniMed 8-K exhibit).

Diabetes was still consolidated in Q1 FY27. From Q3 FY27 onward the reported group will be the three portfolios above, at roughly 42 / 31 / 27.

Geographic mix

Medtronic is close to an even split between the US and the rest of the world. In FY26, US sales were about 50% of the total and international about 50%. Both grew mid-single digits organically, with the US slightly behind (Q4 FY26 release). The prior year's three-way split was US ~51%, non-US developed markets ~30% and emerging markets ~18.5% (company 10-K, via investorroom). In Q1 FY27 the US outgrew international, because the US is where the newest products (PFA, renal denervation, Hugo) are ramping.

How the regions differ:

  • United States. Medicare coverage decisions and hospital value-analysis committees set the pace for new therapies.
  • Western Europe and Japan. Single-payer systems, slower price movement and tender purchasing. Medtronic has sold there for decades and often launches there first: Hugo had a European CE mark years before its US clearance, and Sphere-360 is CE-marked ahead of the US.
  • Emerging markets, China above all. China is both a sales market and a manufacturing base. Pricing there is shaped by government volume-based procurement tenders. Management notes that robotic surgery penetration in emerging markets is about 1% (Q1 FY27 call).
  • Greater China management. In October 2026, Greater China was placed under the newly appointed President, Michael Marinaro (Section 10).

3. Products and Operations

The group has dozens of product lines. The ones that matter to the investment case fall into three groups: the new growth platforms, the large mature franchises, and the enabling capital systems that pull disposables.

The growth platforms

Pulsed field ablation (Affera Sphere-9, Sphere-360, PulseSelect)

  • How it works. PFA destroys heart tissue with very short, high-voltage electric pulses. Cardiomyocytes are more sensitive to these pulses than the oesophagus, phrenic nerve or blood vessels around them, so the energy is selective without heat.
  • The product lines. Medtronic has two. PulseSelect is a single-shot catheter for isolating the pulmonary veins. Affera, acquired in 2022, is a mapping-integrated system. Its Sphere-9 tip can map the heart and also switch between pulsed field and radiofrequency energy.
  • What makes it hard to copy. The Affera console, the mapping software and the catheter work as one closed system, so a hospital that installs the console is buying a workflow.
  • Recent milestones.
    • Sphere-9 launched in Japan in Q4 FY26.
    • CE-mark indications were extended to ventricular arrhythmias in Q1 FY27.
    • Sphere-360, a single-shot circular catheter, is CE-marked and launching in Europe.
    • A US pivotal trial is enrolling for Sphere-360, as is a separately approved US ventricular tachycardia (VT) trial (Q4 FY26 call).
  • Installed base. The US Affera installed base grew more than 35% sequentially in Q1 FY27 (Q1 FY27 call). Every console placed becomes a future stream of single-use catheters.

Renal denervation (Symplicity Spyral, branded Ardian)

  • How it works. A catheter is passed into the renal arteries and delivers radiofrequency energy to quiet the sympathetic nerves that drive blood pressure up.
  • Coverage. FDA approval came in late 2023. The commercial unlock was Medicare: CMS finalised a national coverage determination on 28-29 October 2025, with claims implementation on 6 April 2026. It covers both Medtronic's system and Recor's ultrasound system, under "coverage with evidence development", which means patients are treated within approved registries (Endovascular Today; TCTMD).
  • Next product. A transradial (wrist-access) catheter is due in the second half of FY27.

Hugo robotic-assisted surgery

  • Design. Hugo is a modular, multi-arm soft-tissue robot. Each arm sits on its own cart, unlike the single-boom design of Intuitive's da Vinci. That suits smaller rooms and lets a hospital move arms between rooms.
  • Regulatory path. Hugo was CE-marked in Europe years ago. It received FDA clearance for urologic procedures in December 2025: prostatectomy, nephrectomy and cystectomy, roughly 230,000 US procedures a year. The first US cases were done at Cleveland Clinic in February 2026 (Q3 FY26 call via Investing.com).
  • Pending clearances. A 510(k) for general surgery and gynaecology, plus a robotic LigaSure sealer, was filed in late April 2026.
  • Instruments. The robotic LigaSure Maryland jaw instrument was cleared in September 2026 (Medtronic, 16 Sep 2026).
  • Why the instruments matter. Medtronic's case is that it can put its own sealing and stapling franchises on the robot. Intuitive has had to build or license those.
  • Data layer. Touch Surgery records and analyses the video from each case.
  • International partner. For some international markets Medtronic struck a strategic partnership and investment with Cornerstone Robotics in Q1 FY27, giving it access to Cornerstone's Sentire system.

Stealth AXiS. The next generation of Medtronic's spine and cranial ecosystem combines planning, navigation, imaging and robotics on one platform. It has FDA clearance across spine, cranial and ENT, and a CE mark for spine and cranial. Management's framing on the Q3 FY26 call was "It's not just a new robot. It's not just an extension of Mazor, it's a whole new platform." The commercial logic is the same as Affera's: own the capital in the room and the implants follow.

Altaviva. A small implanted tibial nerve stimulator for urge urinary incontinence, placed at the ankle in a short procedure. Medtronic sizes the US addressable population at around 16 million patients. It had trained more than 500 physicians by Q3 FY26, and procedures doubled sequentially in Q1 FY27.

The large mature franchises

Pacing and defibrillation

  • Micra, the leadless pacemaker, has kept double-digit growth roughly a decade after launch.
  • Conduction system pacing places leads on the heart's own wiring rather than the muscle. It added more than 2 percentage points to CRM growth in Q1 FY27.
  • Aurora EV-ICD puts the defibrillator lead outside the heart, under the breastbone.
  • LINQ insertable monitors feed the diagnosis pipeline.

Evolut TAVR. A self-expanding transcatheter aortic valve, delivered through the leg, that replaces a narrowed valve without open-heart surgery. Growth has slowed to low single digits in a crowded market (Section 5).

Surgical staples, energy and mesh. High-volume, contract-priced and largely a replacement market.

Neuromodulation. Inceptiv closed-loop spinal cord stimulation adjusts the dose to the spinal cord's own signals, and BrainSense adaptive DBS senses brain activity. Both are technically distinctive. The category is soft (Section 8).

Manufacturing and delivery

  • Footprint. The largest plants are in the United States, Puerto Rico, Mexico, China, Ireland, the Dominican Republic, Switzerland, France and Italy. The company employs more than 95,000 people, 44% of them in the US or Puerto Rico (10-K, via search summary).
  • Two kinds of manufacturing. Active implants (pacemakers, neurostimulators) are clean-room electronics assembly with hermetic sealing, battery chemistry and long-term reliability testing. Disposables (staplers, catheters) are high-volume moulding, assembly and sterilisation.
  • Constraints.
    • Sterilisation capacity, including the industry's dependence on ethylene oxide.
    • Validated supplier changes, which need regulatory filings.
    • Tariffs. The China, Mexico and Puerto Rico footprint exposes Medtronic to US trade policy, which management quantified as a multi-hundred-million-dollar cost in FY26 and FY27 (Section 8).
  • Simplification. In Q1 FY27 management said it had cut about 9,000 SKUs to simplify the supply chain.
  • Delivery. Medtronic delivers through a direct sales and clinical-specialist force that attends many implant cases, plus distributors in smaller markets.
  • Value chain in one line: clinical evidence and approval → plant and sterilisation → hospital contract (GPO or tender) → rep-supported procedure → remote monitoring and follow-up (pacing, neuromodulation) → device replacement at battery end-of-life.

4. Customers

Who buys. The paying customer is almost always an institution: a hospital, an integrated delivery network, an ambulatory surgery centre, or a government tender authority abroad. The deciding customer is very often a physician. That split between who pays and who chooses defines the medtech sales model. Medtronic sells to thousands of accounts and no single hospital is meaningful on its own. The concentration that matters sits at two higher levels:

  • Payers. Medicare in the US, and national health systems elsewhere, decide whether a new therapy gets used at all. Renal denervation was largely stalled until the October 2025 national coverage determination.
  • Group purchasing organisations. These negotiate contract prices for commodity-like surgical products on behalf of member hospitals.

How each customer type buys

Implantable and electrophysiology products (pacing, ablation, neuromodulation, spine implants).

  • Who decides. The implanting physician chooses the device. The hospital's value-analysis committee approves the product for use, and supply chain negotiates price.
  • Criteria. Clinical outcomes and evidence, ease of use, procedure time, and the quality of the company's field clinical support. In ablation, mapping integration also matters. In pacing, battery longevity and remote monitoring matter.
  • Sales cycle. Adding a new product line at an account usually takes months, because of committee approval, training and proctoring. Physicians are trained once and stick with what they know.

Capital systems (Affera console, Hugo, Stealth AXiS, O-arm).

  • Who decides. A capital committee with the CFO's office involved.
  • Criteria. Total cost per procedure, utilisation, surgeon demand and service.
  • Sales cycle. Often six to eighteen months, sometimes structured as placements or leases tied to disposable volumes.
  • Why it matters. Once a system is installed, the hospital is effectively committed to that vendor's consumables for years.

Surgical disposables and monitoring (staplers, energy, oximetry).

  • Who decides. Supply chain and operating-room management, within GPO contracts, with surgeon preference as a constraint.
  • Criteria. Price, contract compliance, availability, and breadth of the bundle.
  • Sales cycle. Contract renewals every few years.

Why customers choose Medtronic

  1. Breadth across the same call point. An electrophysiologist can get pacemakers, monitors, defibrillators and ablation from one company with one rep team and one remote-monitoring platform.
  2. Clinical evidence. Medtronic runs large trials, for example SPYRAL in renal denervation and the PFA pivotal studies, which value-analysis committees ask for.
  3. Field support. Its clinical specialists attend cases.
  4. Contract leverage. In surgery, the ability to bundle staplers, energy, mesh and monitoring into a single GPO agreement.

Switching costs. Switching costs are high and come in layers:

  1. Implanted base. A patient with a Medtronic pacemaker usually gets a Medtronic replacement at battery depletion, because the leads in the heart and the programmer in the clinic are Medtronic's.
  2. Capital lock-in. A hospital with an Affera console or a Stealth navigation system has trained staff, validated workflows and sunk capital, so changing vendors means retraining a whole lab.
  3. Regulatory and clinical qualification. A new device has to pass value analysis and physician training before it can be used at all.

These costs are weakest in commodity surgical disposables, where a GPO can switch the default stapler at contract renewal. Even there, surgeon preference slows conversion.

Contract structures and revenue predictability

  • Most revenue is procedure-driven and recurring in practice, though not contractual.
  • Capital systems are sold outright or placed against committed disposable volume.
  • Remote-monitoring services carry recurring fees.
  • Replacement cycles for active implants give a predictable base layer.

The result is that revenue moves with procedure volumes, which are steady across economic cycles (Section 6), plus share shifts in fast-changing categories such as ablation.


5. Competitive Landscape and Moat

Medtronic competes against a different set of rivals in almost every franchise. The useful question is where it is structurally advantaged and where it is a share-taker or share-donor.

CompetitorCountryListingApprox Market Cap (as of Nov 2026)Product OverlapRelative Strength
Johnson & Johnson (MedTech)USNYSE: JNJ~US$546B (group)PFA and mapping (Carto), surgical staplers/energy (Ethicon), spineCarto mapping installed base; Ethicon surgical scale
Abbott LaboratoriesUSNYSE: ABT~US$188BPacing, ICDs, leadless, PFA (Volt), neuromodulation, structuralBroad CRM line; strong in mapping; late in PFA
Intuitive SurgicalUSNasdaq: ISRG~US$154BSoft-tissue robotics vs HugoDominant installed base and training ecosystem
StrykerUSNYSE: SYK~US$118BSpine, neurovascular, surgical capitalStrong hospital capital relationships
Boston ScientificUSNYSE: BSX~US$64BPFA (Farapulse), pacing/ICDs, neuromod, pelvic health (Axonics), interventionalPFA pioneer, now losing share
Edwards LifesciencesUSNYSE: EW~US$62BTAVR vs EvolutLeading TAVR franchise
Becton DickinsonUSNYSE: BDX~US$59BSurgical and hernia products, monitoring adjacenciesHospital consumables scale
Zimmer BiometUSNYSE: ZBH~US$20BSpine and robotics (partial)Orthopaedic channel
Recor MedicalUS (Otsuka group)Private (subsidiary of Otsuka)-Ultrasound renal denervationOnly other covered RDN system

Market caps from companiesmarketcap, November 2026; J&J from search snapshot the same month.

Franchise by franchise

Cardiac ablation: share-taker.

  • Boston Scientific's Farapulse took all of PFA spend in 2023 and around 83% through 2024.
  • Medtronic's PulseSelect launched in January 2024, J&J's Varipulse in December 2024 and Abbott's Volt in January 2026.
  • By early 2026, purchasing data from more than 4,500 US facilities showed Medtronic at about 48% of PFA spend, Boston Scientific 41%, J&J 11% and Abbott about 1% (Qsight/Guidepoint, June 2026).
  • Management said Sphere-9 gained about 9 share points in Q1 FY27.
  • Why Medtronic is winning: Affera puts mapping and ablation in one catheter, and Medtronic already sits in the electrophysiology lab through pacing.
  • Where it can lose: J&J owns the incumbent mapping installed base (Carto), and Boston Scientific is iterating its catheters fast. Its next-generation Farawave Nav took a large slice of spend within its own portfolio.

Pacing and defibrillation: incumbent leader. Medtronic's breadth (Micra, conduction-system pacing, Aurora) and its replacement base make it the reference vendor, with Abbott and Boston Scientific as the main challengers. Market share here moves slowly.

TAVR: number two and stuck. Edwards' Sapien remains the default choice in many US centres. Evolut competes on its self-expanding design and haemodynamics, but growth has slowed to low single digits. Medtronic is investing at the edges, for example its stake in Pi-Cardia's leaflet-modification technology, not attacking head-on.

Renal denervation: duopoly by regulation. Only Medtronic's radiofrequency system and Recor's ultrasound system are FDA-approved and Medicare-covered. Medtronic has the larger trial programme and sales force. The barrier here is evidence plus reimbursement, which a new entrant would need years to replicate.

Soft-tissue robotics: distant challenger.

  • Intuitive's da Vinci has a vast installed base, a surgeon-training pipeline and a full instrument catalogue. That is a network-effect-like moat: residents train on it, hospitals hire for it, and data accumulates on it.
  • Hugo's angles are its modular arms, Medtronic's own energy and stapling instruments, and existing OR relationships.
  • Management says Hugo procedures are growing more than twice the market rate, but from a small base. Hugo is expected to pass 50,000 cumulative procedures by the end of FY27, a fraction of da Vinci's annual volume.
  • This is where Medtronic is weakest relative to its ambitions.

Spine and cranial: the ecosystem player. Globus Medical (merged with NuVasive), Stryker and J&J DePuy Synthes compete on implants. Medtronic differentiates by owning the imaging, navigation and robot. Management notes US spine robotics penetration is still in single digits, so the land grab for installed systems is still live.

Surgical disposables: scale versus J&J. A two-giant market, with Ethicon as the other incumbent. Competition is about contracts, bundling and incremental features. Differentiation is modest and pricing pressure is chronic.

Neuromodulation: crowded and soft. Boston Scientific, Abbott and Nevro compete in spinal cord stimulation. Medtronic's closed-loop technology is a feature advantage in a category whose demand has weakened.

Barriers to entry

  • Regulatory evidence. For Class III implants, the FDA's premarket approval path means multi-year randomised trials and tens of thousands of patient-years of reliability data.
  • Reimbursement. A new therapy needs codes and coverage before hospitals will use it, as renal denervation showed.
  • Clinical sales infrastructure. Supporting cases in thousands of hospitals takes a large field force.
  • Capital lock-in. Installed consoles and robots make conversion slow.

These barriers are very high for implants, high for capital ecosystems, and moderate for surgical disposables. Their weak point is a new technology that changes the procedure itself. PFA showed this when it overturned the thermal-ablation order within three years: Boston Scientific, a challenger, captured the whole category, and then Medtronic reclaimed much of it.

Structural shifts

  • Category resets through new energy modalities and capital platforms. These reward whoever owns the integrated system.
  • Portfolio refocusing across big medtech. Medtronic's own diabetes exit is an example: large companies are shedding slow units to concentrate on faster-growing areas.
  • Government tendering abroad, China's volume-based procurement especially, which compresses prices for commoditised products.

Moat: Wide - switching costs, regulatory or qualification barriers, intangible assets (clinical evidence, brand with physicians), scale

The implanted base, installed consoles and physician training (Section 4) keep customers in place, and the regulatory and reimbursement barriers above keep new entrants out for years. Most of the franchise has held through recessions, the COVID procedure collapse, a well-funded attack from Boston Scientific in ablation, and the HVAD withdrawal and diabetes quality problems of the early 2020s. The moat is wide in implants and electrophysiology, narrower in surgical disposables, and absent in soft-tissue robotics, where Medtronic is the attacker. The thing most likely to erode it is a modality reset like PFA in another core franchise, where an integrated system from a rival makes Medtronic's installed base obsolete faster than Medtronic can replace it.


6. Industry

What drives demand. Medical-device demand rests on three slow, powerful forces:

  1. Ageing populations in rich countries. Heart rhythm disease, valve disease, spinal degeneration, incontinence and Parkinson's all rise steeply with age.
  2. Chronic-disease prevalence. Hypertension affects close to half of US adults on CDC estimates, and many of them stay uncontrolled on drugs.
  3. Technology substitution. Minimally invasive or catheter procedures replace open surgery, and device therapy replaces failing drug therapy.

On top of these sits access: insurance coverage, hospital capacity and the number of trained specialists.

Size and growth. The large-cap medtech categories Medtronic plays in have historically grown in the mid-single digits. Inside them, newer categories grow far faster:

  • PFA moved from zero to the majority of ablation spend within about three years, with thermal contact-force ablation falling to under 8% of ablation spend by early 2026 (Qsight, above).
  • Robotic surgery is still in single-digit penetration in US spine and about 1% in emerging markets, per Medtronic's Q1 FY27 commentary.

Medtronic's own framing is that a portfolio "weighted to higher-growth markets" is what moves a mid-single-digit grower toward high single digits.

Where Medtronic sits in the chain. It is an original-equipment manufacturer and clinical-evidence owner. It sources components (batteries, electronics, polymers, metals) from a supplier base, makes and sterilises finished devices in its own plants, and sells directly to providers. It does not depend on a single critical supplier that is visible in public disclosures. Industry-wide, the sterilisation step, especially ethylene oxide, and specialised electronics are known bottlenecks.

Regulation

  • United States. The FDA's premarket approval (PMA) path covers high-risk implants and 510(k) clearance covers moderate-risk devices. CMS decides Medicare coverage through national coverage determinations and through payment rates for hospitals and ambulatory centres.
  • Europe. The Medical Device Regulation has raised the evidence bar and the cost of keeping older products on the market.
  • China. Volume-based procurement awards national or provincial tenders at steep discounts, which turns some categories into price competitions and favours local manufacturers.
  • Trade. US tariffs on imports from China, Mexico and other sourcing countries became a direct cost line for device makers from 2025.

Cyclicality. Demand is defensive. Pacemakers, defibrillators and stroke devices are not deferrable. Elective procedures such as spine, hernia and some ablations can slip in a downturn or a hospital-capacity crunch, as in 2020, but come back. Capital equipment (robots, navigation) is more sensitive to hospital budgets and interest rates than disposables are.

Industry tailwinds

  • Procedure volumes have been strong since the pandemic.
  • Payers are increasingly willing to cover device therapies that reduce long-term drug and hospitalisation costs, renal denervation being the latest example.
  • Hospitals are shifting toward integrated capital platforms that pull consumables.

Industry headwinds

  • Tariffs and trade friction.
  • Price compression through tenders and GPOs.
  • Rising evidence costs under EU MDR.
  • Category resets that can strand an incumbent's installed base.

7. Growth Triggers

Ranked by how much each could change the business, most material first.

  • Pulsed field ablation keeps compounding: ventricular indications, a single-shot catheter and international launches.

    • Management expects the Cardiac Ablation Solutions franchise to grow about 2.5 times the market rate in FY27, and more than three times in Q2 (Q1 FY27 concall, 1 Sep 2026).
    • The US VT pivotal trial was approved, with enrolment planned in the first half of FY27. The Sphere-360 US pivotal trial is enrolling, and Sphere-360 is launching in Europe (Q4 FY26 concall, 3 Jun 2026).
    • The Japan launch of Sphere-9 began in Q4 FY26 and the European VT label was added in Q1 FY27.
    • Repeated in every concall from Q2 FY26 onward.
  • Hugo moves from urology into general surgery and gynaecology in the US.

    • A 510(k) for general and gynaecologic indications plus robotic LigaSure was filed in late April 2026 (Q4 FY26 concall, 3 Jun 2026). US expansion into those specialties was expected in the fall of 2026 (Q1 FY27 concall, 1 Sep 2026).
    • Management expects Hugo to pass 50,000 completed procedures by the end of FY27, with procedure growth more than twice the market rate (Q1 FY27 concall).
    • Hernia and general surgery have been flagged as the next indications since the Q2 FY26 concall (18 Nov 2025).
  • Renal denervation (Ardian) scales on Medicare coverage and a new catheter.

    • The Medicare NCD has been implemented since April 2026 (Q2 FY26 concall, 18 Nov 2025: "revenue expected to pick up in the back half").
    • A transradial (wrist-access) catheter is on track to launch in the second half of FY27, and the SPYRAL AFFIRM data were accepted as a TCT late-breaker (Q1 FY27 concall, 1 Sep 2026).
    • A direct-to-consumer campaign and a physician finder are being used to build referral flow (Q3 FY26 concall, 17 Feb 2026).
    • Repeated across the last four concalls.
  • Capital redeployment after MiniMed: roughly double the combined R&D and acquisition budget aimed at high-growth segments.

    • Management says it now prioritises categories growing at 20% or more and has stepped up venture investing (Q1 FY27 concall, 1 Sep 2026).
    • Deals already closed or announced: CathWorks (FFRangio coronary physiology), Scientia Vascular (neurovascular guidewires), SPR Therapeutics (peripheral nerve stimulation), plus stakes in Pi-Cardia, Beluga Medical, CardioACC and Cornerstone Robotics (Q4 FY26 and Q1 FY27 concalls).

    "We have aspirations for higher growth than we've done historically." - Geoff Martha, Q1 FY27 concall, 1 Sep 2026

  • Stealth AXiS rollout across spine, cranial and ENT. It is FDA-cleared in all three and CE-marked for spine and cranial. Management frames it as a new ecosystem platform rather than a robot upgrade, and US spine robotics penetration is still in single digits (Q3 FY26 concall, 17 Feb 2026; Q4 FY26 concall; Q1 FY27 concall).

  • Altaviva scales into a large, under-treated incontinence population. Training programmes have been oversubscribed and are being expanded (Q2 FY26 concall). Consumer activation and physician training are being scaled (Q3 FY26 concall). Procedures are ramping (Q1 FY27 concall).

  • Investor Day, 10-11 December 2026, Charlotte, North Carolina. Management will lay out the portfolio roadmap and financial framework for the post-MiniMed company, including business-unit presentations beyond current disclosures (Q1 FY27 concall, 1 Sep 2026).


8. Key Risks

8.1 The PFA lead reverses

  • Mechanism. Section 5 showed how fast share moved in ablation. It can move back just as fast:
    • Boston Scientific is iterating catheters and mapping integration.
    • J&J's Carto installed base is a ready channel for its own PFA catheters.
    • Abbott has only just launched.
  • Pricing. Ablation catheters carry premium prices, and four competitors in the category raise the odds of price compression once the novelty wears off.
  • Why it matters. Management's own guidance leans heavily on ablation growing several times the market rate. That makes this the single largest swing factor for group growth.
  • Calibration. Moderate probability of a slowdown in share gains over two to three years. An outright loss of leadership is lower probability. The impact on the growth narrative would be high.

8.2 New platforms that need behaviour change ramp slower than promised

  • Mechanism. Renal denervation, Hugo and Altaviva each need someone to change habits:
    • Ardian needs primary-care physicians and cardiologists to refer hypertensive patients to an interventionalist. Medicare coverage requires registry participation.
    • Hugo needs surgeons trained on da Vinci to adopt a second console.
    • Altaviva needs urologists and patients to choose an implant over drugs or other stimulators.
  • Evidence from the calls. On the Q3 FY26 call management sounded noticeably less certain about the near-term renal denervation market. When asked about the pace, the executive said the market "will... continue to... be like that in the near term" (Investing.com transcript).
  • Calibration. High probability that at least one of the three disappoints against the narrative. The damage would be moderate, because they are additive to a large core rather than load-bearing.

8.3 Faster M&A and a bigger R&D budget dilute returns

  • Mechanism. After MiniMed, management is roughly doubling the annual R&D-plus-acquisitions budget (Section 7). Small, high-growth targets are bought at full prices and dilute earnings in the early years.
  • Evidence. M&A dilution guidance for FY27 was already raised at the Q4 FY26 call to higher than previously indicated. Medtronic's history includes expensive deals that took years to pay off, and the activist engagement (Section 10) arose partly because shareholders judged the company's growth and returns inadequate.
  • Calibration. Moderate probability, slow-burning impact. It would show up as earnings growth that lags revenue growth.

8.4 Tariffs and the China footprint

  • Mechanism. Medtronic makes products in China, Mexico, Puerto Rico and Ireland and sells into the US. Tariffs cost it a meaningful amount in FY26, and management guided to a larger tariff cost in FY27 (Q3 FY26 and Q4 FY26 concalls).
  • Two-way exposure. China is also a market subject to volume-based procurement, where local competitors are favoured. A further escalation in US-China trade policy would hit cost and revenue together.
  • Calibration. Moderate probability of further escalation. Impact moderate and partly mitigable by moving production, which takes years because it needs regulatory revalidation.

8.5 The slow core drags. About half the remaining group grows slowly or not at all:

  • Evolut TAVR is at low single digits against Edwards.
  • Neuromodulation is soft. The CFO cited "ongoing SCS market softness and replacement headwinds in DBS" in Q1 FY27.
  • Coronary and surgical disposables are mature.

Mechanism. If ablation growth normalises before the new platforms are big enough (8.1 and 8.2), the group growth rate falls back to where it was before the turnaround. Calibration. High probability over a three-year view that the core stays slow. The question is only whether new platforms outrun it.

8.6 A quality or recall event in a flagship franchise

  • Mechanism. Medtronic has precedent. It stopped selling the HVAD heart pump in 2021 after safety problems, and the diabetes business operated under an FDA warning letter in the early 2020s. A field action on a high-volume implant (pacing leads, defibrillators, neurostimulators) or on an ablation catheter early in its life would cost revenue, invite litigation and hand share to rivals.
  • Calibration. Low probability in any given year. Potentially severe for the franchise affected.

9. Walk the Talk

Concalls used:

  • Q4 FY25: 21 May 2025
  • Q1 FY26: 19 August 2025
  • Q2 FY26: 18 November 2025
  • Q3 FY26: 17 February 2026
  • Q4 FY26: 3 June 2026
  • Q1 FY27: 1 September 2026, within 90 days of today

The Q2 FY27 call is scheduled for 24 November 2026.

What was guidedWhen (concall)What happenedVerdict
Separate Diabetes within 18 months, via IPO then split-offQ4 FY25 (May 2025)IPO March 2026; split-off completed 15 Oct 2026, about 17 months after the announcementKept
FY26 organic revenue growth of ~5%Q4 FY25 (May 2025); raised to ~5.5% in Q2 FY26FY26 delivered 5.8% organicKept (beat)
FY26 non-GAAP EPS range set in May 2025, then raised in Nov 2025Q4 FY25; Q2 FY26Cut in March 2026 for MiniMed-related charges; final result landed inside the original May 2025 range but below the raised rangePartly missed (non-operating)
Hugo US FDA clearance for urology in Q3/Q4 FY26Q2 FY26 (Nov 2025)Cleared December 2025; first US cases February 2026Kept
Roughly double the PFA franchise from its FY25 base by early FY27Q2 FY26 (Nov 2025)Ablation franchise grew 70-90% in each of the four quarters since; management says trailing revenue has passed the doubled levelKept
Investor Day in mid-2026Aug 2025 board announcement, reiterated on Q1 FY26 callRescheduled to 10-11 Dec 2026Slipped
High-single-digit EPS growth in FY27Q2 FY26 (Nov 2025); reaffirmed Mar 2026FY27 guidance set, then raised in Q1 FY27, within that bandPending (on track)
Hugo general surgery and gynaecology in the US by fall 2026Q4 FY26; Q1 FY27Filed April 2026; robotic LigaSure Maryland cleared Sep 2026; main indication clearance not confirmed in available disclosuresPending

The EPS guidance cut. This is the one blemish in the table, and how it happened matters. In November 2025 management raised its FY26 earnings range. In March 2026 it cut the range by more than it had raised it. Earlier-than-expected FDA clearance of the MiniMed Flex pump triggered a one-time charge for royalty-like payments owed to Blackstone, which had co-funded the pump's development. The 10% MiniMed IPO also began diluting Medtronic's share of the earnings (8-K, 24 Mar 2026). The company was explicit that the operating business was unchanged:

"...guidance for fiscal year 2027 of high single-digit EPS growth remains unchanged."

FY26 earnings then landed inside the revised range. The underlying business delivered, but a contractual obligation that management should have been able to model turned a raise into a cut within four months. That is a forecasting miss on deal mechanics, not on demand.

The MiniMed separation. When the deadline was set in May 2025, an 18-month two-step separation through IPO markets was not a given. Management hit it, and the exchange offer was 5.4 times subscribed, which let Medtronic exit its whole stake at once rather than leave a stub. In June 2026 Martha had framed the timing this way:

"We are at the right time. We've put a lot of time and money into the business. It's ready to go." - Geoff Martha, Q4 FY26 concall

The Investor Day. The August 2025 board-and-Elliott announcement promised an investor day "in mid-2026" to set out the financial framework. It is now scheduled for December 2026, after the separation closed. The delay is sensible, since a framework for the post-MiniMed company only makes sense after MiniMed is gone. It is still a stated date that moved.

Assessment. On operations, this management has been moderately conservative for the past six quarters. Revenue guidance has been beaten or raised almost every quarter, and the large product milestones (Hugo urology, PFA scale, the diabetes exit) arrived on or ahead of schedule. Where it has stumbled, it has been on corporate-finance mechanics (the Blackstone charge) and calendar slippage on non-operating promises (the Investor Day), not on the business.


10. Ownership, Governance and Shareholder Friendliness

Ownership and control. Medtronic plc is an Irish-incorporated public company with a single class of ordinary shares listed on the NYSE. There is no controlling family, founder, parent or state holder, and the shareholder base is widely spread across institutions. Elliott Investment Management disclosed in August 2025 that it was "among Medtronic's largest investors" without stating a percentage (Medtronic, 19 Aug 2025). The exact stakes of the largest holders are listed in the FY26 proxy beneficial-ownership table, which was not extracted for this report. For a minority holder the structure is straightforward: one share, one vote; full float; and no related-party exposure to a controlling holder. Influence runs through large institutions and, since 2025, an activist.

Governance. The flags worth knowing are these. All are drawn from the FY26 proxy (DEF 14A, Aug 2026) unless noted.

  • Combined Chair and CEO. Geoff Martha holds both roles, balanced by a Lead Independent Director, Craig Arnold, who has served in that role since 2022.
  • Board independence. Eleven of twelve directors are independent.
  • Elliott-era board changes. After engagement with Elliott in August 2025, the board added John Groetelaars (described in the release as former Hillrom President and CEO) and William Jellison (former Stryker CFO). It also created Growth and Operations committees to oversee portfolio moves and margin delivery.
  • Pay. Executive pay is tied to measurable metrics: revenue growth, non-GAAP operating profit, free cash flow and a quality metric in the annual plan, plus performance share units. FY26 annual incentives paid out at 103% of target even though EPS goals were not met.
  • Auditor. PricewaterhouseCoopers. No qualified opinion was noted.
  • CEO background. Per the proxy, Martha worked at GE Healthcare and GE Capital from 1998 to 2011 before joining Medtronic in 2011 as SVP Strategy and Business Development. He became CEO and Chairman in 2020.
  • New President. In October 2026 Michael Marinaro was named President, keeping his MedSurg, Americas and commercial-operations responsibilities and adding Greater China (TradingView/8-K summary). Outside observers will read this as succession bench-building. The company has said nothing about succession.

Capital returns: dividends. Dividends per share declared were:

  • FY24: US$2.76 (US$0.69 a quarter)
  • FY25: US$2.80 (US$0.70 a quarter)
  • FY26: US$2.84 (US$0.71 a quarter)

The quarterly dividend was raised again to US$0.72 for FY27, which the company counts as its 49th consecutive annual increase (Q4 FY25 data via 10-K; Q4 FY26 release). The pattern is a token annual raise of about a cent a quarter. The streak is protected, but the dividend has grown more slowly than earnings.

Capital returns: buybacks and dilution

  • Authorisation and pace. The board authorised US$5.0 billion of repurchases in March 2024, with about US$1.7 billion remaining at 24 October 2025. Net repurchases were about US$2.7 billion in FY25 and about US$1.0 billion in FY26. In FY24, total shareholder returns (dividends plus buybacks) were US$5.5 billion.
  • Last ~90 days. MoatMap's record shows one filing dated 3 September 2026 with consideration lines of US$267 million and US$123 million and no share counts. The US$267 million matches the Q1 FY27 repurchases reported in the earnings release. What the second line represents is not explained in the disclosures reviewed.
  • The MiniMed exchange. The largest reduction in share count came from the MiniMed split-off, not cash buybacks: 55.0 million Medtronic shares were retired in exchange for MiniMed stock in October 2026.
  • Net change in share count.
    • Ordinary shares outstanding were 1,330.4 million on 16 June 2023 (FY23 10-K) and 1,280.0 million on 31 July 2026 (10-Q).
    • After the exchange, the count is roughly 1,225 million, about 8% lower than three years earlier. That figure is derived from the two filings above, not reported directly.
    • About half of that reduction is the split-off and about half is cash buybacks net of option issuance.

Verdict: Returns Capital. A 49-year dividend-raise streak, steady buybacks that have shrunk the share count, and a split-off structured to retire shares rather than hand MiniMed stock out pro rata all point the same way. The caveat is that the stated post-MiniMed priority is now more M&A and R&D, so cash returns may grow more slowly from here.


11. Insider Activities

MoatMap's US Form 4 record is the spine for this section. MoatMap flags that its record has gaps for trades dated mid-November 2025 to early January 2026. For that window, the Form 4 filings on SEC EDGAR were checked directly:

  • Filings dated 21 November 2025 (Smith), 24 November 2025 (Blomquist), 9 December 2025 (Kiil) and 17 December 2025 (Martha) were reviewed.
  • Two other 17 December 2025 Form 4s were not opened.
  • January 2026 had no filings in the EDGAR list.

Recent transactions. Material market trades and notable events, most recent first:

DateInsider (Name & Role)TypeSharesApprox ValueNotes
2026-11-02Michael Marinaro, PresidentGrant (RSU, PSU, options)6,547 RSUs, plus PSUs and optionsn/a (award)Promotion-related award; RSUs vest Aug 2029 (Form 4, 2026-11-04)
2026-10-15Geoffrey Martha, Chairman & CEOOpen-market sale, 10b5-1 plan50,000~US$4.75MPlan adopted 16 Jul 2026; 277,866 shares held directly afterwards (Form 4, 2026-10-15)
2026-10-15Michael Marinaro, then EVP MedSurg & AmericasOpen-market sale10,420~US$1.0MPlan status not confirmed (Form 4, 2026-10-15)
2026-09-16Harry Skip Kiil, EVP & President CardiovascularOpen-market sale1,483~US$0.14MSmall (Form 4, 2026-09-16)
2026-08-03Martha, Pieton, Marinaro, Kiil, Quinn, Thompson, Walter, BlomquistAnnual equity grantsMartha 41,533 RSUs plus PSUs and optionsn/a (award)Routine annual grant cycle (Form 4s, 2026-08-03)
2026-07-08Matthew R. Walter, SVP Chief HR OfficerOpen-market sale3,102~US$0.26MReason not disclosed (Form 4, 2026-07-08)
2026-06-08Harry Skip Kiil, EVP & President CardiovascularOpen-market sale4,189~US$0.34MTwo lots at ~US$80.44 (Form 4, 2026-06-08)
2025-11-19Gregory L. Smith, EVP Global Operations & Supply ChainOpen-market sale29,075~US$2.97MSeven lots at US$101.93-102.08; 46,516 held afterwards; no 10b5-1 footnote seen (Form 4, 2025-11-21)

Not listed individually: routine tax withholding at vesting (for example Martha, 1,564 shares on 15 December 2025, and Kiil, 1,702 shares on 5 December 2025), dividend reinvestment, director annual grants in April 2026, PSU vestings in May 2026, and a 170-share gift by the Chief Accounting Officer in November 2025.

Buys. There were no open-market purchases by any director or officer in the 12 months. MoatMap counts 0 buys, 11 sells and 59 other transactions.

Why the sales happened

  • CEO. Martha's sale was under a Rule 10b5-1 plan adopted on 16 July 2026, three months before execution. The plan was set before the strong Q1 FY27 results were public and before the MiniMed exchange. The sale is under a fifth of his directly held shares plus the August grant, and it leaves his options and unvested awards untouched. This is ordinary diversification for a CEO paid largely in stock.
  • Marinaro. His sale fell on the same day, the day before his promotion to President was announced. The reason was not disclosed in what was reviewed.
  • Smith. His sale at about US$102 in November 2025 was the largest by value in the window apart from the CEO's. The reason was not disclosed.
  • Others. The remaining sales are small relative to the holders' equity awards.

Net assessment. Insiders were small net sellers, with no buying at all. The sales are spread across several executives, are modest relative to their holdings and grant flows, and are at least partly pre-planned. Nothing here signals anything about the business in either direction. The absence of any open-market buying, even during the stock's spring 2026 trough in the low US$80s, means insiders have given no positive signal. Read: neutral.


12. Scenarios

Bull case. PFA becomes Medtronic's Micra moment rather than its Farapulse moment:

  • Affera consoles keep landing in high-volume labs.
  • The ventricular and single-shot catheters extend the lead.
  • Japan and Europe follow the US curve.

Renal denervation finally gets a referral engine as the wrist-access catheter and registry data make it a routine outpatient procedure for drug-resistant hypertension, adding a third large cardiovascular growth leg. Hugo's general-surgery clearance gives it a credible second-source role in hospitals that want leverage over Intuitive, and Stealth AXiS pulls spine implant share. The doubled R&D and acquisition budget buys several small, fast-growing businesses that scale inside Medtronic's channel. In this world, three years from now Medtronic is a cleaner three-portfolio company that grows faster than it has in two decades, the Investor Day framework proves conservative, and the dividend streak extends into its fifties alongside continued share-count reduction.

Base case. Management roughly delivers what it has guided, consistent with a Section 9 record of beating operating guidance:

  • Ablation keeps growing well above the market but decelerates as the category matures and four competitors fight for share.
  • Ardian builds slowly, quarter by quarter, rather than inflecting.
  • Hugo wins its additional indications and grows from a small base without denting Intuitive.
  • Stealth AXiS and Altaviva add steadily.

Tariffs and mature franchises absorb some of the gains. TAVR stays slow and neuromodulation soft. Group growth settles around the upper half of mid-single digits, with earnings growth a little ahead from mix and the diabetes exit. Medtronic looks like a more focused, somewhat faster-growing version of itself, with capital tilting from buybacks toward bolt-on deals.

Bear case. 8.1 and 8.5 compound: Boston Scientific's next-generation catheters and J&J's mapping installed base cap Affera's share gains just as ablation growth normalises, exposing a slow core in TAVR, neuromodulation and surgical disposables. 8.2 means the platforms meant to take over (Ardian, Hugo, Altaviva) are still too small to fill the gap because referral habits and surgeon loyalty barely move. 8.3 then turns the stepped-up acquisition budget into a source of dilution, as management pays up for growth to meet the targets it set at the Investor Day. 8.4 adds tariff cost from the China and Mexico footprint. In this world Medtronic is back to mid-single-digit growth within two to three years, but with a costlier portfolio and an activist shareholder already on the register.

Generated by MoatMap on 16 November 2026. Read it online at moatmap.ai/deep-dive/MDT; today's score is at moatmap.ai/stock/MDT.
Medtronic plc (MDT) Deep Dive - Nov 2026 | MoatMap